Hypertension and ethnicity

Current Opinion in Cardiology

Volumn 31, Issue 4, 2016, Pages 381-386

  Bennett, Amanda ^a   Parto, Parham ^a   Krim, Selim R ^a,b,c  

^a OCHSNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Access to care; Ethnicity; Hypertension; Race; Therapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT; ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; ASIAN; AWARENESS; BLACK PERSON; BLOOD PRESSURE REGULATION; CAUCASIAN; COMORBIDITY; DISEASE CONTROL; DIURETIC THERAPY; ETHNIC DIFFERENCE; ETHNICITY; HEALTH INSURANCE; HUMAN; HYPERTENSION; PATIENT COMPLIANCE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNIC GROUP; ETHNOLOGY; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HISPANIC; MALE;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HISPANIC AMERICANS; HUMANS; HYPERTENSION; MALE;

EID: 84964999950     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000293     Document Type: Review

References (52)

1. Yoon SS, Gu Q, Nwankwo T, et al. Epidemiology/population: trends in blood pressure among adults with hypertension, United States, 2003 to 2012. Hypertension 2015; 65:54-61.
2. Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J Am Soc Hypertens 2015; 9:197-205. The article discusses the prevalence rates of systolic HTN among varying racial groups of untreated adults in the United States.
3. Egan BM, Li J, Hutchinson FN, Ferdinand KC. Hypertension in the United States 1999-2012: progress toward Healthy People 2020 goals. Circulation 2014; 130:1692-1699. The study presents data on prevalence rates of HTN among US adults and the proposed goals for the Healthy People 2020 initiative aimed at decreasing prevalence rates and raising treatment and control rates.
4. Kovesdy CP, Norris KC, Boulware LE, et al. Association of race with mortality and cardiovascular events in a large cohort of US veterans. Circulation 2015; 132:1538-1548. The study provides evidence of lower all cause mortality and CVD risk among black veterans with access to healthcare compared with black individuals in the general US population.
5. Bidulescu A, Francis DK, Ferguson TS, et al. U.S. Caribbean Alliance for Health Disparities Research Group (USCAHDR). Disparities in hypertension among black Caribbean populations: a scoping review by the U. S. Caribbean Alliance for Health Disparities Research Group (USCAHDR). Int J Equity Health 2015; 14:125. The cross-sectional study discusses the racial/ethnic disparities seen in HTN among Afro-Caribbean and Caribbean-origin populations.
6. Shan J, Zhang L, Holmes AA, Taub CC. The impact of race on the prognosis of preclinical diastolic dysfunction: a large multiracial urban population study. Am J Med 2015; 129:222.e1-222.e10.
7. Healthy People 2020 Heart Disease and Stroke. http://www.healthypeople. gov/2020/topics-objectives/topic/heart-disease-and-stroke. [Accessed January 12, 2016]
8. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520. Albeit controversial, these evidence-based guidelines present the most recent recommendations for the management of HTN in various populations.
9. Flack JM, Ference BA, Levy P. Should African Americans with hypertension be treated differently than non-African Americans? Curr Hypertens Rep 2014; 16:409.
10. The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-2997.
11. Holmes L, Hossain J, Ward D, Opara F. Racial/ethnic variability in hypertension prevalence and risk factors in National Health Interview Survey. ISRN Hypertension 2013; 2013: Article ID 257842.
12. Ruwald MH, Ruwald AH, Jons C, et al. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy). J Am Coll Cardiol 2013; 61:1518-1526.
13. Kveiborg B, Major-Petersen A, Christiansen B, et al. Carvedilol in the treatment of chronic heart failure: lessons from The Carvedilol or Metoprolol European Trial. Vasc Health Risk Manag 2007; 3:31-37.
14. Chatterjee S, Biondi-Zoccai G, Abbate A, et al. Benefits of b blockers in patients with heart failure and reduced ejection fraction: network metaanalysis. BMJ 2013; 346:f55.
15. American Community Survey (ACS). United States census bureau. www.factfinder. census.gov. [Accessed 12 August 2015]
16. Still CH, Craven TE, Freedman BI, et al., SPRINT Study Research Group. Baseline characteristics of African Americans in the Systolic Blood Pressure Intervention Trial. J Am Soc Hypertens 2015; 9:670-679. The study discusses the differences seen in the baseline characteristics of participants in SPRINT by race.
17. Ferdinand KC, Elkayam U, Mancini D, et al. Use of isosorbide dinitrate and hydralazine in African-Americans with heart failure 9 years after the African- American Heart Failure Trial. Am J Cardiol 2012; 114:151-159.
18. Sorlie PD, Allison MA, Aviles-Santa ML, et al. Prevalence of hypertension, awareness, treatment and control in the Hispanic community health study/ study of Latinos. Am J Hypertens 2014; 27:793-800.
19. Rodriguez CJ, Allison M, Daviguls M, et al. Status of cardiovascular disease and stroke in Hispanics/Latinos in the United States. Circulation 2014; 130:593-625.
20. Duru OK, Vargas RB, Kermah D, et al. Health insurance status and hypertension monitoring and control in the United States. Am J Hypertens 2007; 20:348-353.
21. Lopez-Jimenez F, Lavie CJ. Hispanics and cardiovascular health and the 'Hispanic Paradox': what is known and what needs to be discovered? Prog Cardiovasc Dis 2014; 57:227-229.
22. Daviglus ML, Pirzada A, Talavera GA. Cardiovascular disease risk factors in the Hispanic/Latino population: lessons from the Hispanic Community Health study/study of Latinos(HCHS/SOL). ProgCardiovasc Dis2014;57:230-236.
23. Schneiderman N, Chirinos DA, Avilés-Santa ML, Heiss G. Challenges in preventing heart disease in Hispanics: early lessons learned from the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Prog Cardiovasc Dis 2014; 57:253-261.
24. Campbell PT, Krim SR, Lavie CJ, Ventura HO. Clinical characteristics, treatment patterns and outcomes of Hispanic hypertensive patients. Prog Cardiovasc Dis 2014; 57:244-252.
25. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. AHA/ASA Guidelines 2014; 45:3754-3832.
26. Ferdinand KC, Nasser SA. Understanding the importance of race/ethnicity in the care of the hypertensive patient. Curr Hypertens Rep 2015; 17:15.
27. Tu W, Pratt JH. A consideration of genetic mechanisms behind the development of hypertension in blacks. Curr Hypertens Rep 2013; 15:108-113.
28. Turban S, Thompson CB, Parekh RS, Appel LJ. Effects of sodium intake and diet on racial differences in urinary potassium excretion: results from the Dietary Approaches to Stop Hypertension (DASH)-Sodium trial. Am J Kidney Dis 2013; 61:88-95.
29. Tu W, Eckert GJ, Hannon TS, et al. Racial differences in sensitivity of blood pressure to aldosterone. Hypertension 2014; 63:1212-1218.
30. Ozkor MA, Rahman AM, Murrow JR, et al. Differences in vascular nitric oxide and endothelium-derived hyperpolarizing factor bioavailability in blacks and whites. Arterioscler Thromb Vasc Biol 2014; 34:1320-1327.
31. Mels CM, Loots I, Schwedhelm E, et al. Nitric oxide synthesis capacity, ambulatory blood pressure and end organ damage in a black and white population: the SABPA study. Amino Acids 2016; 48:801-810.
32. http://www.cdc.gov/nchs/nhanes.htm. [Accessed 4 January 2016]
33. McNamara DM, Tam S, Sabolinski ML, et al. Aldosterone synthase promoter polymorphism predicts outcome in African Americans with heart failure: results from the A-HeFT Trial. J Am Coll Cardiol 2006; 48:1277-1282.
34. Cai G, Cole SA, Haack K, et al. Bivariate linkage confirms genetic contribution to fetal origins of childhood growth and cardiovascular disease risk in Hispanic children. Hum Genet 2007; 121:737-744.
35. Cai G, Cole SA, Butte NF, et al. A quantitative trait locus on chromosome 13q affects fasting glucose levels in Hispanic children. J Clin Endocrinol Metab 2007; 92:4893-4896.
36. Thameem F, Voruganti VS, He X, et al. Genetic variants in the renin-angiotensin system genes are associated with cardiovascular-renal-related risk factors in Mexican Americans. Hum Genet 2008; 124:557-559.
37. Kammerer CM, Gouin N, Samollow PB, et al. Two quantitative trait loci affect ACE activities in Mexican-Americans. Hypertension 2004; 43:466-470.
38. Chobanian AV, Bakris GL, Black HR, et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
39. Cai G, Cole SA, Freeland-Graves JH, et al. Principal component for metabolic syndrome risk maps to chromosome 4p in Mexican Americans: the San Antonio Family Heart Study. Hum Biol 2004; 76:651-665.
40. Voruganti VS, Nath SD, Cole SA, et al. Genetics of variation in serum uric acid and cardiovascular risk factors in Mexican Americans. J Clin Endocrinol Metab 2009; 94:632-638.
41. Scinicariello F, Yesupriya A, Chang MH, Fowler BA. Modification by ALAD of the association between blood lead and blood pressure in the U.S. population: results from the Third National Health and Nutrition Examination Survey. Environ Health Perspect 2010; 118:259-264.
42. Sanada H, Jones JE, Jose PA. Genetics of salt-sensitive hypertension. Curr Hypertens Rep 2011; 13:55-66.
43. Bangalore S, Ogedegbe G, Gyamfi J, et al. Outcomes with angiotensinconverting enzyme inhibitors vs other antihypertensive agents in hypertensive blacks. Am J Med 2015; 128:1195-1203. The study compares the risks of cardiovascular events seen in hypertensive blacks with the use of various antihypertensive agents.
44. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122:290-300.
45. The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373:2103-2116. The recent analysis provides evidence for a more intensive BP control goal of SBP less than 120mmHg compared with the currently recommended goal of SBP less than 140mmHg among various racial groups.
46. Watson RE, Karnchanasorn R, Gossain VV. Hypertension in Asian/Pacific Island Americans. J Clin Hyptertens 2009; 11:148-152.
47. Ursua R, Aguilar D, Wyatt L, et al. Awareness, treatment and control of hypertension among Filipino immigrants. J Gen Intern Med 2014; 29:455-462.
48. Zhao B, Jose PO, Pu J, et al. Racial/ethnic differences in hypertension prevalence, treatment, and control for outpatients in northern California 2010-2012. Am J Hypertens 2015; 28:631-639. The cross-sectional study discusses the racial/ethnic differences seen among varying hypertensive minority groups.
49. López-Candales A. Importance of the Hispanic heritage regarding diagnosis and management of hypertension. Postgrad Med 2015; 127:571-572. The study provides epidemiological data regarding the prevalence of HTN rates among Hispanic populations and the associated cardiovascular consequences.
50. Perez A. Acculturation, health literacy, and illness perceptions of hypertension among Hispanic adults. J Transcult Nurs 2015; 26:386-394. The study suggests the importance of acculturation and health literacy in illness perceptions among Hispanics, as well as presenting the disproportionately lower HTN treatment rates in this group.
51. Basu S, Hong A, Siddiqi A. Using decomposition analysis to identify modifiable racial disparities in the distribution of blood pressure in the United States. Am J Epidemiol 2015; 182:345-353.
52. Lackland DT. Racial differences in hypertension: implications for high blood pressure management. Am J Med Sci 2014; 348:135-138.